psblondonbestrestaurants

The Capital **

psblondonbestrestaurants:

Легендарный ресторан. 

Ресторан, который обладает 2 звездами Мишлена и находится в одном из самых престижных отелей в Лондоне. Главный шеф - повар Эрик Чавот, благодаря своему новаторскому подходу и мастерству, вдохновляет своих последователей на 5 континентах. Стоит отметить, что “The Capital” предлагает своим посетителям прекрасный выбор вин.  Уже больше 30 лет  “The Capital” привлекает гурманов со всего мира.

image

  • Адрес: The Capital Hotel, 22 Basil Street, London SW3 1AT
  • Тел.: +44 (0)20 7589 5171
  • Станция метро: Knightsbridge

Read More

70sscifiart
70sscifiart:

"I would stare at the beautiful illustrations on games like Defender, Missile Command, and Breakout for hours, letting that art be the bridge between the imaginary world I’d conjured and my pixelated adventures on our Zenith TV. From that early age, I got a great sense of the significant power in artwork, and packaging as a crucial part of the brand experience."
Your latest 70s Sci-Fi Art reading suggestion: How Atari Made Me A Designer
[Hexanine]

70sscifiart:

"I would stare at the beautiful illustrations on games like Defender, Missile Command, and Breakout for hours, letting that art be the bridge between the imaginary world I’d conjured and my pixelated adventures on our Zenith TV. From that early age, I got a great sense of the significant power in artwork, and packaging as a crucial part of the brand experience."

Your latest 70s Sci-Fi Art reading suggestion: How Atari Made Me A Designer

[Hexanine]

The expected launch of Novartis’s new heart failure drug next year promises to be the company’s most exciting ever and profit margins on the medicine will be good, its head of pharmaceuticals said on Sunday. The Swiss drugmaker impressed doctors at the European Society of Cardiology meeting in Barcelona at the weekend by unveiling strikingly good clinical trial results for the drug, known as LCZ696, in a keenly awaited clinical trial. Investigators working on the study and the company itself believe it has potential to replace drugs that have been central to treating heart failure for a quarter of century, opening up a multibillion-dollar sales opportunity. “It will be possibly the most exciting launch the company has ever had,” David Epstein told an investor meeting.

The expected launch of Novartis’s new heart failure drug next year promises to be the company’s most exciting ever and profit margins on the medicine will be good, its head of pharmaceuticals said on Sunday. The Swiss drugmaker impressed doctors at the European Society of Cardiology meeting in Barcelona at the weekend by unveiling strikingly good clinical trial results for the drug, known as LCZ696, in a keenly awaited clinical trial. Investigators working on the study and the company itself believe it has potential to replace drugs that have been central to treating heart failure for a quarter of century, opening up a multibillion-dollar sales opportunity. “It will be possibly the most exciting launch the company has ever had,” David Epstein told an investor meeting.